New Brunswick Family Medicine · 200 patients
Good evening, Dr. Rivera.
6 trials fit your patients, with 5 pre-screen candidates between them. Ranked by how many of your patients could join. We pre-screened your panel against 39 open trials on Oct 11, 2026; patient records never left your practice.
Advanced Solid Tumors
REGN13089-M404-M2980
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body). The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial…
- Ages
- 18+
- Sex
- All
- Enrolling
- 320
- Ends
- Mar 2031
Advanced Solid Tumor
89Zr˗DFO˗REGN5054
This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features that may be important to the way the immune system fights cancer. The aim of the study is…
- Ages
- 18+
- Sex
- All
- Enrolling
- 50
- Ends
- May 2027
Cancer-Associated Thrombosis
REGN7508
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are…
- Ages
- 18+
- Sex
- All
- Enrolling
- 1,120
- Ends
- Jan 2030
Colo-rectal Cancer
Cemiplimab
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different…
- Ages
- 18+
- Sex
- All
- Enrolling
- 79
- Ends
- Apr 2029
Metastatic Castration-Resistant Prostate Cancer
REGN5678
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of…
- Ages
- 18+
- Sex
- All
- Enrolling
- 345
- Ends
- Nov 2027
Melanoma
REGN10597
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study…
- Ages
- 18+
- Sex
- All
- Enrolling
- 240
- Ends
- Feb 2030
No candidates in your panel· 50
Open trials where none of your patients pre-screened as a candidate or for chart review, or that haven't been pre-screened yet.
Advanced Melanoma
Fianlimab
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
- Ages
- 18+
- Sex
- All
- Enrolling
- 88
- Ends
- Sep 2027
Head and Neck Cancer
Cetuximab
The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to…
- Ages
- 18+
- Sex
- All
- Enrolling
- 40
- Ends
- Jun 2027
Melanoma
Fianlimab
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and…
- Ages
- 18+
- Sex
- All
- Enrolling
- 560
- Ends
- Mar 2027
Recurrent Lung Non-Small Cell Carcinoma
Cemiplimab
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a…
- Ages
- 18+
- Sex
- All
- Enrolling
- 378
- Ends
- Dec 2027
Prostate Cancer
BPX-601
This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is looking at: * What side effects BPX-601 might cause * What is the best dose of…
- Ages
- 18+
- Sex
- Male
- Enrolling
- 36
- Ends
- Feb 2030
Epithelial Ovarian Cancer
Cemiplimab
This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2)…
- Ages
- 18+
- Sex
- Female
- Enrolling
- 90
- Ends
- May 2030
Metastatic Castration-resistant Prostate Cancer
REGN4336
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main purpose of the study is to look at the safety, tolerability (how the body reacts…
- Ages
- 18+
- Sex
- Male
- Enrolling
- 228
- Ends
- Mar 2030
Non-Small Cell Lung Cancer
Cemiplimab
ARCH is a randomised, stratified, multicentre, phase III trial. Protocol treatment consists of cemiplimab, 350 mg i.v., every 3 weeks, for 4 cycles, followed by 700 mg i.v., every 6 weeks for 6 cycles or until relapse or unacceptable toxicities, whichever occurs first. The primary objective of the study is to…
- Ages
- 18+
- Sex
- All
- Enrolling
- 390
- Ends
- Mar 2029
Prostate Cancer
REGN5678
A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab
- Ages
- 18+
- Sex
- Male
- Enrolling
- 60
- Ends
- May 2027
Advanced Renal Cell Carcinoma
Fianlimab
This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.
- Ages
- 18+
- Sex
- All
- Enrolling
- 120
- Ends
- Nov 2029
High-Grade Glioma
Cemiplimab
This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs"). The study is focused on children and young adults with recurrent or progressive High-Grade Glioma (HGG) or ependymoma. "Recurrent" means…
- Ages
- 0–39
- Sex
- All
- Enrolling
- 120
- Ends
- Aug 2032
Locally Advanced Basal Cell Carcinoma
Cemiplimab
This study will test an experimental Regeneron drug called cemiplimab ("study drug") given alone or in combination with other anti-cancer drugs ("combination treatment") to see if they can help treat laBCC. The study is looking at: * What side effects cemiplimab, alone or in a combination treatment, might cause * How…
- Ages
- 18+
- Sex
- All
- Enrolling
- 135
- Ends
- Nov 2030
Nasopharyngeal Carcinoma
Cemiplimab
The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.
- Ages
- 18+
- Sex
- All
- Enrolling
- 60
- Ends
- Jul 2030
Ovarian Cancer
REGN5668
This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main purposes of this…
- Ages
- 18+
- Sex
- Female
- Enrolling
- 612
- Ends
- Nov 2028
Non Small Cell Lung Cancer
Ubamatamab
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and…
- Ages
- 18+
- Sex
- All
- Enrolling
- 300
- Ends
- Jun 2030
Head and Neck Squamous Cell Carcinoma
FDC fianlimab+cemiplimab
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form. The study is…
- Ages
- 18+
- Sex
- All
- Enrolling
- 120
- Ends
- Jun 2028
Nsclc
Cemiplimab
This research study is being done to find out if a drug called cemiplimab is safe in adult patients who have non-small cell lung cancer (NSCLC) that can be surgically removed (resectable Stage II, IIIA, or select IIIB NSCLC). The purpose of this study is also to look at how well the study drug works and whether…
- Ages
- 18+
- Sex
- All
- Enrolling
- 30
- Ends
- Sep 2030
Colorectal Cancer
Cemiplimab
The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with microsatellite stable (MSS) locally advanced rectal cancer (T2 node-positive, T3…
- Ages
- 18+
- Sex
- All
- Enrolling
- 66
- Ends
- Jul 2030
Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Cemiplimab
To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.
- Ages
- 18+
- Sex
- All
- Enrolling
- 17
- Ends
- May 2027
Kidney Transplant Recipient
Cemiplimab
This is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell carcinoma. The hypothesis being tested is that cemiplimab alongside standardized immune…
- Ages
- 18+
- Sex
- All
- Enrolling
- 22
- Ends
- Mar 2031
Clear Cell Renal Cell Carcinoma
Cemiplimab 350 MG Intravenous Solution
The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients with oligometastatic clear cell renal cell carcinoma after completion of radiation therapy.
- Ages
- 18+
- Sex
- All
- Enrolling
- 72
- Ends
- Aug 2029
Pancreatic Ductal Adenocarcinoma
Cemiplimab Plus Gemcitabine
This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose Non-Fermentable (SWI/SNF) alterations who have already been treated with FOLFIRINOX…
- Ages
- 18+
- Sex
- All
- Enrolling
- 43
- Ends
- Jul 2028
Cutaneous Basal Cell Carcinoma
Cemiplimab
Basal cutaneous cell carcinoma (BCC) is the most common skin cancer. Early-stage disease is managed with surgery or radiation that cure more than 95% of patients. Surgical excision is the treatment of choice and by far the most convenient and effective means of achieving cure of any invasive BCC, Surgery is rarely…
- Ages
- 18+
- Sex
- All
- Enrolling
- 18
- Ends
- Dec 2028
Colon Cancer
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
This is a research study to test whether two immunotherapy drugs-cemiplimab and fianlimab-can safely and effectively shrink colon tumors before surgery in people with stage II-III colon cancer that has not spread to other parts of the body. Participants will receive two doses of the study drugs through an IV (one on…
- Ages
- 18+
- Sex
- All
- Enrolling
- 24
- Ends
- Dec 2028
Colorectal Cancer
Cemiplimab
The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater or in patients age 18 or greater considered poor candidates for surgery…
- Ages
- 18+
- Sex
- All
- Enrolling
- 44
- Ends
- May 2030
Melanoma BRAF V600E/K Mutated
Cemiplimab+fianlimab
Brain metastases in patients with advanced and metastatic melanoma are a frequent complication and a significant cause of morbidity and mortality in this patient population. As the incidence of brain metastases continues to increase in patients with metastatic melanoma, it is urgent that the investigators identify…
- Ages
- 18+
- Sex
- All
- Enrolling
- 33
- Ends
- Jan 2028
Basal Cell Carcinoma
Cemiplimab
The study is an open-label, singel arm, prospective, multicenter phase II trial evaluating the efficacy and safety of Cemiplimab when applied as first-line therapy in patients with locally advanced basal cell carcinoma (BCC), which were not pretreated with hedgehog inhibitors (HHI).
- Ages
- 18+
- Sex
- All
- Enrolling
- 34
- Ends
- Oct 2028
Colon and Rectal Cancer
Cemiplimab
This study is being conducted to find out if treatment with gemcitabine, cisplatin, nab-paclitaxel, and cemiplimab can shrink previously inoperable tumors enough for surgery.
- Ages
- 18+
- Sex
- All
- Enrolling
- 20
- Ends
- Jan 2028
Bladder Cancer
Cemiplimab
The goal of this clinical trial is to learn if gemcitabine/cisplatin plus cemiplimab with or without fianlimab works to treat bladder cancer in adults. The main question it aims to answer is: Can gemcitabine, cisplatin, and cemiplimab with or without fianlimab treat bladder cancer? Participants will be randomly…
- Ages
- 18+
- Sex
- All
- Enrolling
- 36
- Ends
- Dec 2028
Ovarian Cancer
Ubamatamab
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs…
- Ages
- 18+
- Sex
- Female
- Enrolling
- 297
- Ends
- Jun 2028
Glioblastoma
Cemiplimab
This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma. Patients will be enrolled…
- Ages
- 18+
- Sex
- All
- Enrolling
- 99
- Ends
- Feb 2031
Merkel Cell Carcinoma
Cemiplimab-Rwlc
The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
- Ages
- 18+
- Sex
- All
- Enrolling
- 36
- Ends
- Mar 2028
Non-small Cell Lung Cancer Stage III
Cemiplimab-Rwlc
The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with select N3 lymph node involvement or other high-risk subsets in which there is no consensus on resectability. The…
- Ages
- 18+
- Sex
- All
- Enrolling
- 21
- Ends
- Dec 2027
Merkel Cell Carcinoma, Stage I
Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph…
- Ages
- 18+
- Sex
- All
- Enrolling
- 135
- Ends
- Dec 2029
NSCLC
Cemiplimab
The goal of IMMUNOLIFE2 is to overcome primary resistance to immune checkpoint inhibitors (ICIs), such as pembrolizumab or nivolumab used alone or in combination with chemotherapy, observed in patients with advanced non-small cell lung cancer (NSCLC) following antibiotic exposure, which induces intestinal dysbiosis.…
- Ages
- 18+
- Sex
- All
- Enrolling
- 162
- Ends
- Sep 2030
Lung Cancer
Cemiplimab
This is a single arm phase II trial enrolling patients with stage II-IIIA non-small cell lung cancer whose disease is deemed amenable for surgical resection and has a PD-L1 level of ≥50%. Patients will receive cemiplimab for 3 cycles followed by surgical resection. The primary endpoint evaluated by the study is the…
- Ages
- 18+
- Sex
- All
- Enrolling
- 33
- Ends
- Dec 2027
Solid Tumors
Cemiplimab
To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.
- Ages
- 18+
- Sex
- All
- Enrolling
- 40
- Ends
- Sep 2028
Carcinoma, Non-Small-Cell Lung
Cemiplimab
The goal of this clinical trial is to learn if Cemiplimab with chemotherapy or Cemiplimab with stereotactic body radiation therapy (SBRT) works as treatment for stages IB, II, and III (N2) Non-Small Cell Lung Cancer (NSCLC). Before surgery to remove their lung cancer, participants will take: 1. Cemiplimab with…
- Ages
- 18+
- Sex
- All
- Enrolling
- 112
- Ends
- Dec 2026
Non Small Cell Lung Cancer
Cemiplimab 350 mg IV
Traditionally, chemotherapy and/or immunotherapy are combined with surgery or radiotherapy to cure patients with lung cancer. However, some patients treated with immunotherapy appear to be cured before surgery or radiotherapy. In this study, patients with a high chance to respond to immunotherapy will be selected.…
- Ages
- 18+
- Sex
- All
- Enrolling
- 30
- Ends
- Dec 2029
Metastatic Castration-Resistant Prostate Cancer
REGN15505
This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC. The goal is to explore new ways to treat these cancers by helping immune cells target and destroy cancer cells. The study will evaluate the use…
- Ages
- 18+
- Sex
- All
- Enrolling
- 265
- Ends
- Oct 2030
Metastatic Castration-Resistant Prostate Cancer
REGN21353
This study will test an experimental Regeneron drug called REGN21353 ("study drug") to see if it can help treat previously treated prostate cancer that has spread (also called metastatic castration-resistant prostate cancer or mCRPC). Some participants may get additional experimental drugs in combination with…
- Ages
- 18+
- Sex
- Male
- Enrolling
- 192
- Ends
- Jul 2031
Ovarian Cancer
Ubamatamab
The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer. The main questions it aims to answer are: * What is the safety profile of ubamatamab when administered with carboplatin-paclitaxel ± bevacizumab? * What is…
- Ages
- 18+
- Sex
- Female
- Enrolling
- 43
- Ends
- Sep 2028
Metastatic Uveal Melanoma
ZIV-Aflibercept
The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can…
- Ages
- 18+
- Sex
- All
- Enrolling
- 32
- Ends
- Oct 2030
Cutaneous Squamous Cell Carcinoma
Cemiplimab
This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called Programmed cell Death-1 (PD-1) on the surface of certain immune…
- Ages
- 18+
- Sex
- All
- Enrolling
- 369
- Ends
- May 2030
Recurrent Ovarian Cancer
Ubamatamab
The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well…
- Ages
- 18+
- Sex
- Female
- Enrolling
- 890
- Ends
- May 2027
Any Advanced Solid Tumors
Sarilumab
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the patient's treating physician. Patients will be sequentially enrolled into the single-arm…
- Ages
- 18+
- Sex
- All
- Enrolling
- 41
- Ends
- Aug 2029
NSCLC
Cemiplimab
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
- Ages
- 18+
- Sex
- All
- Enrolling
- 76
- Ends
- Aug 2027
Pleural Mesotheliomas
Cemiplimab
This is a multicentre, phase IIR, double non-comparative arm trial, with an initial safety run for the anti-LAG3 arm. Approximately 40 sites will participate in the study and will enroll 126 patients with treatment-naive, unresectable malignant PM. Treatment will be administered in 21-day cycles and will continue…
- Ages
- 18–75
- Sex
- All
- Enrolling
- 126
- Ends
- May 2028
HPV-Related Squamous Cell Carcinoma
Cemiplimab
To determine if it is feasible to use neoadjuvant immunotherapy (or immunotherapy plus chemotherapy) to reduce treatment intensity and improve long-term quality of life while maintaining very high cure rates.
- Ages
- 18+
- Sex
- All
- Enrolling
- 32
- Ends
- Jun 2027
Anaplastic Thyroid Cancer
Cemiplimab
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).
- Ages
- 18+
- Sex
- All
- Enrolling
- 12
- Ends
- Mar 2028